Roche works to mitigate US tariff impact with exemption plea
Roche is working to mitigate potential impacts from tariffs by moving production of its medicines to the U.S.…
Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth
Novartis’ CEO remains unfazed by the threat of a newly approved oral PCSK9 inhibitor in Merck & Co.’s…
Novartis CEO pay soars 30% to $32M in 2025
Novartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs…